Population-specific mutation patterns in breast tumors from African American, European American, and Kenyan patients.
Wei TangFlora ZhangJung S ByunTiffany H DorseyHarris G YfantisAnuoluwapo AjaoHuaitian LiuMargaret S PichardoCatherine M PichardoAlexandra R HarrisXiaohong R YangJonine D FigueroaShahin SayedFrancis W MakokhaStefan AmbsPublished in: Cancer research communications (2023)
Women of African descent have the highest breast cancer mortality in the United States and are more likely than women from other population groups to develop an aggressive disease. It remains uncertain to what extent breast cancer in Africa is reminiscent of breast cancer in African American or European American patients. Here, we performed whole exome sequencing of genomic DNA from 191 breast tumor and non-cancerous adjacent tissue pairs obtained from 97 African American, 69 European American, 2 Asian American, and 23 Kenyan patients. Our analysis of the sequencing data revealed an elevated tumor mutational burden in both Kenyan and African American patients, when compared to European American patients. TP53 mutations were most prevalent, particularly in African American patients, followed by PIK3CA mutations, which showed similar frequencies in European American, African American, and the Kenyan patients. Mutations targeting TBX3 were confined to European Americans and those targeting the FBXW7 tumor suppressor to African American patients whereas mutations in the ARID1A gene that are known to confer resistance to endocrine therapy were distinctively enriched among Kenyan patients. A KEGG pathway analysis could link FBXW7 mutations to an increased mitochondrial oxidative phosphorylation capacity in tumors carrying these mutations. Lastly, COSMIC mutational signatures in tumors correlated with the occurrence of driver mutations, immune cell profiles, and neighborhood deprivation with associations ranging from being mostly modest to occasionally robust. To conclude, we found mutational profiles that were different between these patient groups. The differences concentrated among genes with low mutation frequencies in breast cancer.
Keyphrases
- african american
- end stage renal disease
- ejection fraction
- prognostic factors
- type diabetes
- skeletal muscle
- drug delivery
- single cell
- patient reported outcomes
- young adults
- risk assessment
- physical activity
- genome wide
- mesenchymal stem cells
- coronary artery disease
- bone marrow
- cancer therapy
- artificial intelligence
- case report
- cardiovascular events
- transcription factor
- protein kinase